Dividend Safety Check: SPHY Faces Late-Cycle Pressure
SPHY has delivered monthly income since 2012, but 2026 tests whether its high-yield payout can withstand cyclical str...
Discover why dividend ETFs incur fees, including management costs and tracking errors, and how those charges influence your long-term results.
26,393 articlesSPHY has delivered monthly income since 2012, but 2026 tests whether its high-yield payout can withstand cyclical str...
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Oil markets stabilize as July opens, setting up a three-stock energy play. Exxon, Chevron, and ConocoPhillips offer d...
Strategy reports a second BTC sale in six weeks, expanding liquidity and reshaping long-term exposure to crypto.
Three blue-chip names have slipped on the chart while trading below intrinsic value, offering income and upside for p...
PepsiCo drives growth with international momentum while Procter & Gamble shines in beauty; both set the stage for a d...
Pfizer has reset its growth trajectory with big bets on Seagen and a future GLP-1 drug. This analysis breaks down wha...
This in-depth look breaks down SAIC's saic (saic) 2026 earnings landscape, weighing revenue drivers, margins, and ris...
Nvidia is set to outline how it will deploy its cash as AI demand drives growth. The company still pays a token divid...
Two beverage giants, same shelves, different revenue stories. This article breaks down why Coca-Cola often feels stea...
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Two oil giants enter 2026 with contrasting plays: Occidental Petroleum pares back, focusing on the Permian, while Exx...